Department of Obstetrics & Gynecology.
Division of Gynecologic Oncology, Northwestern University Feinberg School of Medicine.
Clin Obstet Gynecol. 2023 Mar 1;66(1):22-35. doi: 10.1097/GRF.0000000000000765. Epub 2022 Nov 21.
Racial inequities are well-documented across the gynecologic oncology care continuum, including the representation of racial and ethnic minoritized groups (REMGs) in gynecologic oncology clinical trials. We specifically reviewed the scope of REMG disparities, contributing factors, and strategies to improve inclusion. We found systematic and progressively worsening under-enrollment of REMGs, particularly of Black and Latinx populations. In addition, race/ethnicity data reporting is poor, yet a prerequisite for accountability to recruitment goals. Trial participation barriers are multifactorial, and successful remediation likely requires multi-level strategies. More rigorous, transparent data on trial participants and effectiveness studies on REMG recruitment strategies are needed to improve enrollment.
种族不平等现象在妇科肿瘤学护理连续体中得到了充分的记录,包括在妇科肿瘤学临床试验中少数民族群体(REMGs)的代表性。我们特别审查了 REMG 差异的范围、促成因素以及改善包容性的策略。我们发现 REMGs 的系统性和逐渐恶化的参与不足,特别是黑人族裔和拉丁裔人口。此外,种族/族裔数据报告很差,但这是对招募目标负责的前提。试验参与障碍是多方面的,成功的补救措施可能需要多层次的策略。需要更严格、透明的试验参与者数据和针对 REMG 招募策略的有效性研究,以提高参与率。